Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Daniel Present, MD, New York

Digestive Disease Associates of Rockland, Pomona

Long Island Clinical Research Assoc., Great Neck

NY Center for Clinical Research, Lake Success

University of Pittsburgh Medical Center, Pittsburgh

Altoona Center for Clinical Research, Duncansville

Chevy Chase Clinical Research, Chevy Chase

Capital Gastroenterology Consultants, P.A., Silver Spring

Maryland Clinical Trials, Annapolis

Gastrointestinal Specialists, Richmond

Le Bauer Research, P.A., Greensboro

Charlotte Gastroenterology & Hepatology, Charlotte

Carolina Digestive Health Associates, Charlotte

Carolina Research Associates, Charlotte

Wilmington Gastroenterology, Wilmington

Columbia Gastro Associates, Columbia

Gastroenterology Consultants, Ormond Beach

V.A. Medical Center, Gainsville

Mark Lamet, MD, Hollywood

Clinical Research of West Florida, Inc., Clearwater

Nashville Medical Research, Nashville

Gastroenterology Center of the Mid South, Memphis

University Hospitals of Cleveland, Cleveland

Indianapolis Gastroenterology Research Foundation, Indianapolis

St. Vincent Hospital: Research Department, Indianapolis

Discovery Research Inteternational, LLC, Milwaukee

Wisconsin Center for Advanced Research, Milwaukee

Northwest Gastroenterology, Arlington Heights

Northwestern University, Chicago

The University of Chicago, Chicago

Washington University School of Medicine, St Louis

Washington University School, St Louis

Gastroenterology & Hematology, Kansas City

Glenn Gordon, MD, Mexico

Drug Research Services, Inc., Metairie

Western States Clinical Research, Arvada

UCSF San Francisco General Hospital, San Francisco

Cal-West, Inc., San Francisco

Westhills Gastroenterology, Portland

Thornton Hospital Reumatology Division, La Jolla

Gastroenterology Associates of Fairfield County, Bridgeport

Clinical Pharmacology Study Group, Worcester

Mayo Clinic Research, Rochester